Literature DB >> 1370428

Left ventricular insulin-like growth factor I increases in early renal hypertension.

H Wåhlander1, J Isgaard, E Jennische, P Friberg.   

Abstract

Increasing interest has been directed toward the possible role of trophically acting molecules as modulators or initiators, or both, of myocardial hypertrophy. The aim of the present study was to investigate the possible role of one such molecule, namely, insulin-like growth factor I, in myocardial hypertrophy developed in response to renal artery stenosis. Two-kidney, one clip Goldblatt hypertension was induced in Wistar rats weighing 180 g, and sham-operated animals were used as controls. Blood pressure was increased as early as 2 days after clipping (133 +/- 4 versus 116 +/- 4 mm Hg, p less than 0.05), and the increase persisted 4 and 7 days after clipping (148 +/- 6 versus 129 +/- 3 mm Hg, p less than 0.01 and 171 +/- 5 versus 139 +/- 3 mm Hg, p less than 0.01, respectively). Left ventricular weight followed a similar pattern (373 +/- 7 versus 350 +/- 8 mg, NS, 415 +/- 11 versus 386 +/- 9 mg, p less than 0.01, and 466 +/- 11 versus 391 +/- 10 mg, p less than 0.01 at 2, 4, and 7 days after clipping, respectively), but no changes in body weight between the groups were observed. Insulin-like growth factor I messenger RNA (mRNA) was quantified using a solution hybridization assay. After 4 days of renal hypertension, there was a significant increase in left ventricular insulin-like growth factor I mRNA (2.0 x 10(-18) +/- 0.48 x 10(-18) versus 0.4 x 10(-18) +/- 0.07 x 10(-18) mol.microgram DNA-1), which was no longer detectable 7 days after clipping.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370428     DOI: 10.1161/01.hyp.19.1.25

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

1.  Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women.

Authors:  Luxia Zhang; Gary C Curhan; John P Forman
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

2.  The potential for growth hormone in the management of heart failure.

Authors:  J P Monson; G M Besser
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

3.  Salidroside Mitigates Sepsis-Induced Myocarditis in Rats by Regulating IGF-1/PI3K/Akt/GSK-3β Signaling.

Authors:  He He; Xiayun Chang; Jin Gao; Lingpeng Zhu; Mingxing Miao; Tianhua Yan
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

4.  The effect of insulin-like growth factor-1 on adult rat cardiac contractility.

Authors:  N S Freestone; S Ribaric; W T Mason
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

Review 5.  Role of growth hormone in chronic heart failure. Therapeutic implications.

Authors:  M Volterrani; F Manelli; M Cicoira; R Lorusso; A Giustina
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 6.  Clinical practice. Renal-artery stenosis.

Authors:  Lance D Dworkin; Christopher J Cooper
Journal:  N Engl J Med       Date:  2009-11-12       Impact factor: 91.245

7.  Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.

Authors:  M Brink; J Wellen; P Delafontaine
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 8.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes.

Authors:  M Y Donath; J Zapf; M Eppenberger-Eberhardt; E R Froesch; H M Eppenberger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

10.  Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure.

Authors:  R L Duerr; S Huang; H R Miraliakbar; R Clark; K R Chien; J Ross
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.